Effects of subinhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells

P. C. Braga, G. Piatti, E. Conti, F. Vignali

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

At present, only a limited number of studies of the effects of sub-inhibitory antifungal agents on the adherence of Candida to epithelial (buccal and vaginal) host cells are available. The adherence of Candida albicans to the epithelial cell surface is accepted as an important first step in persistent colonization and in the following symptomatic or asymptomatic infection of mucosal surface. Ciclopirox (ciclopiroxolamine, CAS 29342-05-0) is a substituted pyridone antimycotic drug, unrelated to the imidazole derivatives and its topical application ensures maximum local bioavailability. The present study was done to investigate the effects of sub-inhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. The findings on the adherence of different strains of Candida indicate that the drug caused a significant reduction in the mean number of Candida adhering to both buccal and vaginal cells. This reduction was maximal at concentration of 1/2 MIC and still significant at 1/4 , 1/8, 1/16 MIC, but with progressive return to mean control values at 1/32 MIC. Ciclopirox acts on fungi by inhibiting the intracellular uptake of essential substrates and ions and this probably acts on the Candida ability to express its adherence mechanisms.

Original languageEnglish
Pages (from-to)1368-1371
Number of pages4
JournalArzneimittel-Forschung/Drug Research
Volume42
Issue number11
Publication statusPublished - 1992

Fingerprint

ciclopirox
Cheek
Candida
Candida albicans
Epithelial Cells
Pyridones
Asymptomatic Infections
Antifungal Agents
Pharmaceutical Preparations
Biological Availability
Fungi
Ions

Keywords

  • antimycotics
  • Candida albicans, cell adherence
  • CAS 29342-05-0
  • ciclopirox, in vitro studies

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Effects of subinhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. / Braga, P. C.; Piatti, G.; Conti, E.; Vignali, F.

In: Arzneimittel-Forschung/Drug Research, Vol. 42, No. 11, 1992, p. 1368-1371.

Research output: Contribution to journalArticle

@article{a0796b57e8c14335afffbaa1fbed1988,
title = "Effects of subinhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells",
abstract = "At present, only a limited number of studies of the effects of sub-inhibitory antifungal agents on the adherence of Candida to epithelial (buccal and vaginal) host cells are available. The adherence of Candida albicans to the epithelial cell surface is accepted as an important first step in persistent colonization and in the following symptomatic or asymptomatic infection of mucosal surface. Ciclopirox (ciclopiroxolamine, CAS 29342-05-0) is a substituted pyridone antimycotic drug, unrelated to the imidazole derivatives and its topical application ensures maximum local bioavailability. The present study was done to investigate the effects of sub-inhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. The findings on the adherence of different strains of Candida indicate that the drug caused a significant reduction in the mean number of Candida adhering to both buccal and vaginal cells. This reduction was maximal at concentration of 1/2 MIC and still significant at 1/4 , 1/8, 1/16 MIC, but with progressive return to mean control values at 1/32 MIC. Ciclopirox acts on fungi by inhibiting the intracellular uptake of essential substrates and ions and this probably acts on the Candida ability to express its adherence mechanisms.",
keywords = "antimycotics, Candida albicans, cell adherence, CAS 29342-05-0, ciclopirox, in vitro studies",
author = "Braga, {P. C.} and G. Piatti and E. Conti and F. Vignali",
year = "1992",
language = "English",
volume = "42",
pages = "1368--1371",
journal = "Arzneimittel-Forschung/Drug Research",
issn = "0004-4172",
publisher = "Editio Cantor Verlag GmbH",
number = "11",

}

TY - JOUR

T1 - Effects of subinhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells

AU - Braga, P. C.

AU - Piatti, G.

AU - Conti, E.

AU - Vignali, F.

PY - 1992

Y1 - 1992

N2 - At present, only a limited number of studies of the effects of sub-inhibitory antifungal agents on the adherence of Candida to epithelial (buccal and vaginal) host cells are available. The adherence of Candida albicans to the epithelial cell surface is accepted as an important first step in persistent colonization and in the following symptomatic or asymptomatic infection of mucosal surface. Ciclopirox (ciclopiroxolamine, CAS 29342-05-0) is a substituted pyridone antimycotic drug, unrelated to the imidazole derivatives and its topical application ensures maximum local bioavailability. The present study was done to investigate the effects of sub-inhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. The findings on the adherence of different strains of Candida indicate that the drug caused a significant reduction in the mean number of Candida adhering to both buccal and vaginal cells. This reduction was maximal at concentration of 1/2 MIC and still significant at 1/4 , 1/8, 1/16 MIC, but with progressive return to mean control values at 1/32 MIC. Ciclopirox acts on fungi by inhibiting the intracellular uptake of essential substrates and ions and this probably acts on the Candida ability to express its adherence mechanisms.

AB - At present, only a limited number of studies of the effects of sub-inhibitory antifungal agents on the adherence of Candida to epithelial (buccal and vaginal) host cells are available. The adherence of Candida albicans to the epithelial cell surface is accepted as an important first step in persistent colonization and in the following symptomatic or asymptomatic infection of mucosal surface. Ciclopirox (ciclopiroxolamine, CAS 29342-05-0) is a substituted pyridone antimycotic drug, unrelated to the imidazole derivatives and its topical application ensures maximum local bioavailability. The present study was done to investigate the effects of sub-inhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. The findings on the adherence of different strains of Candida indicate that the drug caused a significant reduction in the mean number of Candida adhering to both buccal and vaginal cells. This reduction was maximal at concentration of 1/2 MIC and still significant at 1/4 , 1/8, 1/16 MIC, but with progressive return to mean control values at 1/32 MIC. Ciclopirox acts on fungi by inhibiting the intracellular uptake of essential substrates and ions and this probably acts on the Candida ability to express its adherence mechanisms.

KW - antimycotics

KW - Candida albicans, cell adherence

KW - CAS 29342-05-0

KW - ciclopirox, in vitro studies

UR - http://www.scopus.com/inward/record.url?scp=0026498114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026498114&partnerID=8YFLogxK

M3 - Article

C2 - 1492854

AN - SCOPUS:0026498114

VL - 42

SP - 1368

EP - 1371

JO - Arzneimittel-Forschung/Drug Research

JF - Arzneimittel-Forschung/Drug Research

SN - 0004-4172

IS - 11

ER -